These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 21807639

  • 1. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
    Blank PR, Moch H, Szucs TD, Schwenkglenks M.
    Clin Cancer Res; 2011 Oct 01; 17(19):6338-46. PubMed ID: 21807639
    [Abstract] [Full Text] [Related]

  • 2. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group.
    J Natl Cancer Inst; 2009 Sep 02; 101(17):1182-92. PubMed ID: 19666851
    [Abstract] [Full Text] [Related]

  • 3. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM.
    Int J Cancer; 2012 Jul 15; 131(2):438-45. PubMed ID: 21898389
    [Abstract] [Full Text] [Related]

  • 5. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 10; 27(35):5924-30. PubMed ID: 19884556
    [Abstract] [Full Text] [Related]

  • 6. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.
    J Med Econ; 2013 Dec 20; 16(12):1387-98. PubMed ID: 24102083
    [Abstract] [Full Text] [Related]

  • 10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec 20; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 11. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.
    Clin Colorectal Cancer; 2011 Dec 20; 10(4):325-32. PubMed ID: 21729677
    [Abstract] [Full Text] [Related]

  • 12. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
    Genet Med; 2013 Jul 20; 15(7):517-27. PubMed ID: 23429431
    [Abstract] [Full Text] [Related]

  • 13. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.
    Crit Rev Oncol Hematol; 2011 Jun 20; 78(3):243-51. PubMed ID: 20619672
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
    Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV.
    J Natl Cancer Inst; 2012 Dec 05; 104(23):1785-95. PubMed ID: 23197490
    [Abstract] [Full Text] [Related]

  • 15. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.
    Eur J Cancer; 2010 Jul 05; 46(11):1997-2009. PubMed ID: 20413299
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.
    Oncology; 2014 Jul 05; 87(1):7-20. PubMed ID: 24968756
    [Abstract] [Full Text] [Related]

  • 17. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E.
    Oncology; 2010 Jul 05; 79(5-6):415-22. PubMed ID: 21474966
    [Abstract] [Full Text] [Related]

  • 18. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M.
    Cytopathology; 2011 Dec 05; 22(6):358-64. PubMed ID: 21029218
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
    Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.
    Value Health; 2013 Dec 05; 16(2):288-96. PubMed ID: 23538180
    [Abstract] [Full Text] [Related]

  • 20. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T.
    Clin Colorectal Cancer; 2015 Jun 05; 14(2):91-8. PubMed ID: 25666295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.